GlassScriptPhysician profile
Veronica L Zollo
NPI 1306155148
$2,026.54
in general payments reported to CMS, 2019-2025
30 companies · $222 in 2025
The $222 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $601 · 2022: $605 · 2023: $318 · 2024: $280 · 2025: $222.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $821.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $820.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $446.10 | 2021-2025 | |
| Novo Nordisk INC | $198.46 | 2021-2025 | Ozempic, Rybelsus |
| Amgen INC. | $138.16 | 2021-2024 | Repatha, Otezla, Evenity |
| Pfizer INC. | $134.94 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $120.87 | 2021-2022 | |
| Amarin Pharma, INC. | $105.53 | 2021-2022 | |
| Astellas Pharma US INC | $99.02 | 2023-2025 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $83.16 | 2021-2023 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $82.55 | 2021-2025 | Airsupra |
| Lilly USA, LLC | $68.69 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Dexcom, INC. | $52.40 | 2022-2023 | Dexcom G6 Transmitter |
| Eisai INC. | $48.79 | 2021-2025 | |
| Sanofi Pasteur INC. | $48.36 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $46.57 | 2021-2022 | |
| Hologic Sales and Service, LLC | $36.39 | 2022-2024 | Aptima, Thinprep 2000 Processor |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $33.36 | 2021 | |
| Nestle Healthcare Nutrition INC. | $30.10 | 2021-2022 | |
| Dynavax Technologies Corporation | $27.17 | 2022-2024 | Heplisav-B |
| Teva Pharmaceuticals USA, INC. | $25.74 | 2025 | Austedo Xr |
| Supernus Pharmaceuticals, INC. | $24.88 | 2022 | |
| Corium, LLC | $21.62 | 2023 | Azstarys |
| Inspire Medical Systems, INC. | $21.49 | 2024 | Inspire |
| Sanofi-Aventis U.S. LLC | $20.24 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.55 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $17.64 | 2022 | |
| Paratek Pharmaceuticals, INC. | $16.88 | 2021 | |
| Axsome Therapeutics, INC. | $16.54 | 2025 | Symbravo |
| Bayer Healthcare Pharmaceuticals INC. | $16.54 | 2025 | |
| Horizon Therapeutics Plc | $14.10 | 2021 | |
| Antares Pharma, INC. | $11.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Veronica Zollo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.